glp 1 and chronic kidney disease The cardiovascular renal effects of glucagon-like peptide receptor agonists in patients with advanced diabetic | Cardiovascular Diabetology Combination therapy as a new

Review cost and access : Align prescriptions with insurance coverage to support long-term adherence

And when you consider that most conditions like [01:01:00] hypothyroidism that primarily affect women do not get the research, the funding or even the medication development and interventions and access to care in the same way that I mean, erectile dysfunction does, then we can be grateful that we do have access to these and we can be judicious because To use it the right time in the right place at the lowest dose to get us the benefits we need and potentially with a plan, it's not always a promise, but potentially a plan to not have to need them lifelong

Meanwhile, the Pentagon is pushing a parallel effort aimed at the same population: mandatory testosterone screening for troops over 30 to treat what it calls Operator Syndrome. The FDA advisory panel voted last week to recommend that the agency allow compounding pharmacies to legally dispense six popular peptides, two of which have become a popular choice in special operations

There are two GLP-1 pills: Wegovy (semaglutide) was the first GLP-1 pill approved for weight loss in December 2025

Why researchers combine them The two peptides target mechanistically distinct pathways